Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Down 5.8% – Should You Sell?

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) were down 5.8% on Monday . The company traded as low as $27.33 and last traded at $27.33. 37,775 shares traded hands during trading, a decline of 90% from the average session volume of 377,997 shares. The stock had previously closed at $29.00.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on DMRA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Wedbush boosted their target price on shares of Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Thursday, July 30th. HC Wainwright restated a “buy” rating and set a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Jefferies Financial Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They set a “buy” rating and a $50.00 price target on the stock. Finally, TD Cowen raised shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, August 24th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $44.00.

Damora Therapeutics, Inc. Common Stock Trading Down 8.4%

The stock has a 50-day simple moving average of $29.22 and a 200 day simple moving average of $26.80. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -7.88 and a beta of 1.47.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. As a group, research analysts forecast that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current fiscal year.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

A number of large investors have recently bought and sold shares of the company. Ikarian Capital LLC acquired a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth approximately $6,574,000. Boothbay Fund Management LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at approximately $2,204,000. Jain Global LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at approximately $2,774,000. Remedium Capital Partners LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at $2,772,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at $266,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical?stage biotechnology company developing small?molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin?3, an extracellular carbohydrate?binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase?like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin?3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin?3 inhibitor being evaluated for systemic fibrotic disorders.